Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Some Common Post-Merger Compliance Issues

This article was originally published in The Gold Sheet

Executive Summary

Merging drug makers sometimes try to make do with minimal staffing of quality and compliance units – with unfortunate results, FDA’s Edwin Rivera-Martinez told the PDA/FDA conference in Washington last month.

You may also be interested in...



Woodcock: The US FDA Sets The Stage For Global Quality Dossiers

New approach could eliminate minor differences among authorities, enabling pharmaceutical manufacturing processes to become truly global.

Human-Machine Interface Ratted On Apollo Workers Who Fibbed Batch Data

The US FDA applied laboratory data integrity inspection technique to production floor, leading to warning letter, import alert.

Don’t Let Trade Issues Interfere With Drug Inspection Coordination, Experts Say

US National Academies panel diverges on how to focus pharmaceutical inspectorates’ mutual reliance arrangements on public health goals.

UsernamePublicRestriction

Register

PS000554

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel